>
Ultimovacs ASA logo

ULTI - Ultimovacs ASA Share Price

NOK69 2.0  3.0%

Last Trade - 06/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £192.1m
Enterprise Value £153.4m
Revenue £n/a
Position in Universe 732nd / 1838
Bullish
Bearish
Unlock ULTI Revenue
Momentum
Relative Strength (%)
1m +5.87%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -23.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
8.43 5.78 0.000 0.000 0.000 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Ultimovacs ASA revenues was not reported. Net lossincreased 97% to NOK120.6M. Higher net loss reflectsExternal R&D expenses increase of 82% to NOK64.7M (expense), Other payroll related expenses increase of 56% to NOK44.2M(expense), Share-based payments increase from NOK8.2M(income) to NOK6.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ULTI Revenue Unlock ULTI Revenue

Net Income

ULTI Net Income Unlock ULTI Revenue

Normalised EPS

ULTI Normalised EPS Unlock ULTI Revenue

PE Ratio Range

ULTI PE Ratio Range Unlock ULTI Revenue

Dividend Yield Range

ULTI Dividend Yield Range Unlock ULTI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ULTI EPS Forecasts Unlock ULTI Revenue
Profile Summary

Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 29, 2011
Public Since June 3, 2019
No. of Shareholders: n/a
No. of Employees: 21
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Oslo Stock Exchange
Shares in Issue 31,973,511
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ULTI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ULTI
Upcoming Events for ULTI
Tuesday 11th May, 2021
Q1 2021 Ultimovacs ASA Earnings Release
Friday 20th August, 2021
Q2 2021 Ultimovacs ASA Earnings Release
Frequently Asked Questions for Ultimovacs ASA
What is the Ultimovacs ASA share price?

As of 06/05/21, shares in Ultimovacs ASA are trading at NOK69, giving the company a market capitalisation of £192.1m. This share price information is delayed by 15 minutes.

How has the Ultimovacs ASA share price performed this year?

Shares in Ultimovacs ASA are currently trading at NOK69 and the price has moved by 54.88% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ultimovacs ASA price has moved by 21.52% over the past year.

What are the analyst and broker recommendations for Ultimovacs ASA?

There are no analysts currently covering Ultimovacs ASA.

When will Ultimovacs ASA next release its financial results?

Ultimovacs ASA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Ultimovacs ASA dividend yield?

Ultimovacs ASA does not currently pay a dividend.

Does Ultimovacs ASA pay a dividend?

Ultimovacs ASA does not currently pay a dividend.

When does Ultimovacs ASA next pay dividends?

Ultimovacs ASA does not currently pay a dividend.

How do I buy Ultimovacs ASA shares?

To buy shares in Ultimovacs ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Ultimovacs ASA?

Shares in Ultimovacs ASA are currently trading at NOK69, giving the company a market capitalisation of £192.1m.

Where are Ultimovacs ASA shares listed? Where are Ultimovacs ASA shares listed?

Here are the trading details for Ultimovacs ASA:

Country of listing: Norway
Exchange: OSL
Ticker Symbol: ULTI
What kind of share is Ultimovacs ASA?

Based on an overall assessment of its quality, value and momentum, Ultimovacs ASA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Ultimovacs ASA share price forecast 2021?

Shares in Ultimovacs ASA are currently priced at NOK69. At that level they are trading at 26.09% discount to the analyst consensus target price of 0.00.

Analysts covering Ultimovacs ASA currently have a consensus Earnings Per Share (EPS) forecast of -4.705 for the next financial year.

How can I tell whether the Ultimovacs ASA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ultimovacs ASA. Over the past six months, the relative strength of its shares against the market has been 13.3%. At the current price of NOK69, shares in Ultimovacs ASA are trading at 14.19% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Ultimovacs ASA PE Ratio?

We were not able to find PE ratio data for Ultimovacs ASA.

Who are the key directors of Ultimovacs ASA?

We were unable to find the directors for Ultimovacs ASA.

Who are the major shareholders of Ultimovacs ASA?

Here are the top five shareholders of Ultimovacs ASA based on the size of their shareholding:

Gjelsten Holding AS Corporation
Percentage owned: 19.29% (6.17m shares)
Canica AS Investment Advisor
Percentage owned: 7.84% (2.51m shares)
Sundt AS Investment Advisor
Percentage owned: 7.68% (2.46m shares)
Inven2 AS Corporation
Percentage owned: 5.83% (1.87m shares)
WATRIUM AS Corporation
Percentage owned: 5.44% (1.74m shares)
Similar to ULTI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.